2. Gene
  3. Btk - Bruton tyrosine kinase Gene

Btk - Bruton tyrosine kinase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：布鲁顿酪氨酸激酶

种属: Rattus norvegicus

基因 ID: 367901 | 基因类型: protein coding

关于 Btk

Primary_assembly X: 97,722,802-97,761,853 reverse strand.mRatBN7.2:CM026994.1

This gene has 3 transcripts (splice variants), 206 orthologues, 32 paralogues and is associated with 36 phenotypes. Biased expression in Spleen (RPKM 217.2), Thymus (RPKM 46.2) and 3 other tissues.

功能概要

该基因编码的蛋白可启动蛋白酪氨酸激酶活性。涉及多个过程，包括细胞对真菌来源分子的反应；肥大细胞分泌组胺；和超敏反应的积极调节。位于细胞质的核周区。用于研究阿瑟斯反应。该基因的人类直系同源物与无丙种球蛋白血症有关（多个）；孤立性生长激素缺乏症 III 型；和淋巴瘤（多发性）。与人类 BTK（布鲁顿酪氨酸激酶）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables protein tyrosine kinase activity. Involved in several processes, including cellular response to molecule of Fungal origin; histamine secretion by mast cell; and positive regulation of hypersensitivity. Located in perinuclear region of cytoplasm. Used to study arthus reaction. Human ortholog(s) of this gene implicated in agammaglobulinemia (multiple); isolated growth hormone deficiency type III; and lymphoma (multiple). Orthologous to human Btk (Bruton tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Btk 基因产物(1)

mRNA Protein Name
NM_001007798.2 NP_001007799.2 tyrosine-protein kinase BTK
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables protein tyrosine kinase activity IDA
IDA: 通过直接分析推断
7696342 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in cellular response to molecule of fungal origin IDA
IDA: 通过直接分析推断
10744701 RGD
involved in cellular response to reactive oxygen species IMP
IMP: 通过突变表型推断
10744701 RGD
involved in eosinophil homeostasis IMP
IMP: 通过突变表型推断
32484067 RGD
involved in histamine secretion by mast cell IMP
IMP: 通过突变表型推断
12220673 RGD
involved in monocyte proliferation IMP
IMP: 通过突变表型推断
32484067 RGD
involved in negative regulation of B cell activation IMP
IMP: 通过突变表型推断
25545336 RGD
involved in negative regulation of interleukin-10 production IMP
IMP: 通过突变表型推断
28352114 RGD
involved in negative regulation of leukocyte proliferation IMP
IMP: 通过突变表型推断
32484067 RGD
involved in neutrophil homeostasis IMP
IMP: 通过突变表型推断
32484067 RGD
involved in peptidyl-tyrosine autophosphorylation IMP
IMP: 通过突变表型推断
21521773 RGD
involved in positive regulation of B cell proliferation IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of immunoglobulin production IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of interleukin-17A production IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of interleukin-6 production IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of phagocytosis IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of synoviocyte proliferation IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of tumor necrosis factor production IMP
IMP: 通过突变表型推断
28352114 RGD
involved in positive regulation of type I hypersensitivity IMP
IMP: 通过突变表型推断
22228807 RGD
involved in positive regulation of type III hypersensitivity IMP
IMP: 通过突变表型推断
22228807 RGD
involved in protein autophosphorylation IDA
IDA: 通过直接分析推断
7696342 RGD
involved in proteoglycan catabolic process IMP
IMP: 通过突变表型推断
32083858 RGD
involved in response to lipopolysaccharide IMP
IMP: 通过突变表型推断
28352114 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in perinuclear region of cytoplasm IDA
IDA: 通过直接分析推断
12220673 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Btk 蛋白结构

PH_Btk

PH_Btk: cd01238 (5 - 167)

SH3_BTK

SH3_BTK: cd11906 (218 - 272)

SH2_Tec_Btk

SH2_Tec_Btk: cd10397 (275 - 379)

PTKc_Btk_Bmx

PTKc_Btk_Bmx: cd05113 (398 - 653)

  • 0
  • 200
  • 400
  • 600
  • 661 a.a.
蛋白主名 其他名称

tyrosine-protein kinase BTK

Bruton agammaglobulinemia tyrosine kinase

相关产品

Approval
生物活性分子 (8)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10997 Ibrutinib Inhibitor 99.97% 是
HY-17600 Acalabrutinib Inhibitor 99.88% 是
HY-101474A Zanubrutinib Inhibitor 99.71% 是
HY-129390 Orelabrutinib Inhibitor 99.97% 是
HY-15771 Tirabrutinib Inhibitor 99.71% 是
HY-10997A Ibrutinib Racemate Inhibitor 95.13% 否
HY-15771A Tirabrutinib hydrochloride Inhibitor 99.43% 是
HY-101474AR Zanubrutinib (Standard) Inhibitor / 否
Clinical Phase
生物活性分子 (20)
目录号 产品名 作用方式
纯度 Phase
HY-131328 Pirtobrutinib Inhibitor 99.88% Phase 3
HY-19834 Fenebrutinib Inhibitor 99.42% Phase 3
HY-109192 Tolebrutinib Inhibitor 99.79% Phase 3
HY-128757 Remibrutinib Inhibitor 99.76% Phase 3
HY-112166 Rilzabrutinib Inhibitor 99.37% Phase 3
HY-132842 Sunvozertinib Inhibitor 99.92% Phase 3
HY-19816 Avitinib Inhibitor 99.95% Phase 3
HY-19816A Avitinib maleate Inhibitor 99.86% Phase 3
HY-112215 Nemtabrutinib Inhibitor 98.64% Phase 2
HY-18012 Spebrutinib Inhibitor 99.22% Phase 2
HY-112161 Branebrutinib Inhibitor 99.82% Phase 2
HY-109078 Vecabrutinib Inhibitor 99.76% Phase 2
HY-109010 Poseltinib Inhibitor 98.08% Phase 2
HY-101856 BMS-986142 Inhibitor 99.53% Phase 2
HY-18012A Spebrutinib besylate Inhibitor / Phase 2
HY-153220 NX-2127 Inhibitor 99.72% Phase 1
HY-153321 NX-5948 Degrader 99.33% Phase 1
HY-139535 Luxeptinib Inhibitor 99.30% Phase 1
HY-139984 BIIB091 Inhibitor 99.85% Phase 1
HY-132879 TAK-020 Inhibitor 99.93% Phase 1
Pre-clinical Phase
生物活性分子 (162)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-100342 Ibrutinib-biotin Inhibitor 99.93% 否
HY-80003 QL47 Inhibitor 98.11% 否
HY-11999 CGI-1746 Inhibitor 99.39% 否
HY-101215 Evobrutinib Inhibitor 98.70% 是
HY-122562 MT-802 Inhibitor 98.94% 否
HY-18009 (Z)-LFM-A13 Inhibitor 99.80% 否
HY-80002 BMX-IN-1 Inhibitor 99.04% 否
HY-133137 SJF620 Inhibitor 98.98% 否
HY-P5438 Srctide Substrate 99.93% 否
HY-101474 (±)-Zanubrutinib Inhibitor 99.70% 否
HY-109143 Elsubrutinib Inhibitor ≥98.0% 否
HY-139481 TL-895 Inhibitor 99.86% 否
HY-100335 PCI-33380 Inhibitor ≥98.0% 否
HY-13943 CNX-774 Inhibitor 99.92% 否
HY-144288 BLK-IN-2 Inhibitor 98.72% 否
HY-43521 Ibrutinib-MPEA 99.71% 否
HY-153803 GBD-9 Inhibitor 99.76% 否
HY-18010 PCI 29732 Inhibitor 99.86% 否
HY-130983 N-piperidine Ibrutinib hydrochloride Inhibitor 98.06% 否
HY-18951 ONO-4059 analog Inhibitor 99.74% 否
HY-18018 RN486 Inhibitor 99.87% 否
HY-100338 CNX-500 Inhibitor 99.88% 否
HY-153357 NRX-0492 Degrader 98.16% 否
HY-101941 BTK IN-1 Inhibitor 98.01% 否
HY-13036A IBT6A Inhibitor 99.43% 否
HY-15427 GDC-0834 Inhibitor 98.05% 否
HY-150023 BI-1622 Inhibitor 98.97% 否
HY-153110A Larotinib mesylate hydrate Inhibitor 98.66% 否
HY-78727 Ibrutinib deacryloylpiperidine Inhibitor 99.97% 否
HY-124645 QL-X-138 Inhibitor 99.77% 否
HY-160141 BTK-IN-29 Inhibitor 97.19% 否
HY-131342 BIIB068 Inhibitor 99.69% 否
HY-15805 KIN-8194 Inhibitor 98.01% 否
HY-17600S Acalabrutinib-d4 Inhibitor 99.50% 否
HY-135334 ACP-5862 Inhibitor 98.41% 否
HY-101474B (R)-Zanubrutinib 98.97% 否
HY-132808 Atuzabrutinib Inhibitor 98.01% 否
HY-147943 PROTAC BTK Degrader-1 98.87% 否
HY-122830 DD-03-171 Degrader 98.72% 否
HY-10997S Ibrutinib-d5 Inhibitor 98.08% 否
HY-163565 BIIB129 Inhibitor 99.54% 否
HY-101766 Btk inhibitor 2 Inhibitor 99.57% 否
HY-101793 BMS-935177 Inhibitor 99.11% 否
HY-101474S Zanubrutinib-d5 Inhibitor ≥99.0% 否
HY-100659 Dihydrodiol-Ibrutinib Inhibitor 99.92% 否
HY-15427A GDC-0834 Racemate 98.04% 否
HY-136531 XMU-MP-3 Inhibitor 98.27% 否
HY-125997 BTK inhibitor 10 Inhibitor 99.66% 否
HY-153220A (R)-NX-2127 Degrader / 否
HY-149051 BGB-8035 Inhibitor 99.00% 否
HY-153110 Larotinib Inhibitor 99.50% 否
HY-132842A (S)-Sunvozertinib Inhibitor 99.14% 否
HY-15427B GDC-0834 S-enantiomer 98.03% 否
HY-153245 JNJ-64264681 Inhibitor 98.14% 否
HY-137438 Edralbrutinib Inhibitor 99.75% 否
HY-133137A SJF620 hydrochloride Inhibitor 99.28% 否
HY-131705 BTK inhibitor 17 Inhibitor 99.53% 否
HY-110002 LFM-A13 Inhibitor 99.65% 否
HY-160246 QL47B Inhibitor / 否
HY-109143B (R)-Elsubrutinib Inhibitor ≥98.0% 否
HY-131328A (R)-Pirtobrutinib 99.78% 否
HY-110013 Terreic acid Inhibitor / 否
HY-101522 CHMFL-EGFR-202 Inhibitor 99.75% 否
HY-13036 (Rac)-IBT6A Inhibitor 98.18% 否
HY-160245 QL47R 99.94% 否
HY-160246A QL47B TFA Inhibitor / 否
HY-13036B IBT6A hydrochloride Inhibitor 99.72% 否
HY-157763 PROTAC BTK Degrader-8 Degrader / 否
HY-156746 DBt-10 Degrader / 否
HY-130255 BTK inhibitor 13 Inhibitor / 否
HY-115876 BTK-IN-5 Inhibitor / 否
HY-132196 BTK inhibitor 18 Inhibitor / 否
HY-151808 JS25 Inhibitor 98.37% 否
HY-156604 Cinsebrutinib Inhibitor / 否
HY-101521 CHMFL-BTK-01 Inhibitor / 否
HY-145373 BMS-986143 Inhibitor / 否
HY-151211 BTK-IN-16 Inhibitor / 否
HY-100659S Dihydrodiol-Ibrutinib-d5 Inhibitor / 否
HY-153951S BTK-IN-26 Inhibitor / 否
HY-170413 PROTAC BTK Degrader-12 Degrader / 否
HY-142932 BTK-IN-6 Inhibitor / 否
HY-147741 DPPY Inhibitor / 否
HY-162280 PROTAC BTK Degrader-9 Degrader / 否
HY-101474BS (R)-Zanubrutinib-d5 / 否
HY-P10609 Btk substrate peptide / 否
HY-143716 JAK3/BTK-IN-1 Inhibitor / 否
HY-144283 BLK-IN-1 Inhibitor / 否
HY-169228 WS-11 Inhibitor / 否
HY-143900 BTK-IN-7 Inhibitor / 否
HY-151920 BTK-IN-17 Inhibitor / 否
HY-163295 BTK degrader-1 Degrader / 否
HY-153536 PROTAC BTK Degrader-3 Inhibitor / 否
HY-162081 BTK-IN-32 Inhibitor / 否
HY-154860 PTD10 Degrader / 否
HY-150885 BTK ligand 1 Degrader / 否
HY-111781 Civorebrutinib Inhibitor / 否
HY-135334S ACP-5862-d4 Inhibitor / 否
HY-147580 BTK-IN-10 Inhibitor / 否
HY-147584 BTK-IN-14 Inhibitor / 否
HY-163183 JAK3/BTK-IN-7 Inhibitor / 否
HY-156969 Topoisomerase I inhibitor 11 / 否
HY-123117 VA5 Inhibitor / 否
HY-124153 GNE-431 Inhibitor / 否
HY-148585 BTK-IN-22 Inhibitor / 否
HY-168302 BTK ligand 10 / 否
HY-162407 I-As-1 Inhibitor / 否
HY-158064 BTK-IN-36 Inhibitor / 否
HY-142621 BCPyr Inhibitor / 否
HY-163827 ABBV-992 Inhibitor / 否
HY-147784 HZ-A-005 Inhibitor / 否
HY-152201 BTK-IN-18 Inhibitor / 否
HY-W062695 (R)-Acalabrutinib Inhibitor / 否
HY-159947 PROTAC BTK Degrader-11 Degrader / 否
HY-143901 EGFR-IN-40 Inhibitor / 否
HY-150752 BTK-IN-15 Inhibitor / 否
HY-163962 L18I / 否
HY-115944 BTK-IN-9 Inhibitor / 否
HY-147581 BTK-IN-11 Inhibitor / 否
HY-156743 DCAF1 binder 2 Degrader / 否
HY-156553 BTK-IN-27 Inhibitor / 否
HY-157159 BTK-IN-28 Inhibitor / 否
HY-149391 PROTAC BTK Degrader-6 Degrader / 否
HY-143719 JAK3/BTK-IN-4 Inhibitor / 否
HY-160219S BTK-IN-33 Inhibitor / 否
HY-143720 JAK3/BTK-IN-5 Inhibitor / 否
HY-117900A (Rac)-PF-06250112 / 否
HY-151961 RSH-7 Inhibitor 99.07% 否
HY-152212 BTK-IN-19 Inhibitor / 否
HY-147582 BTK-IN-12 Inhibitor / 否
HY-148832 BTK-IN-20 Inhibitor / 否
HY-136113 Ibrutinib dimer Inhibitor / 否
HY-110113 CTA056 Inhibitor / 否
HY-162257 BTK-IN-34 Inhibitor / 否
HY-148594 BTK-IN-23 Inhibitor / 否
HY-160966 PROTAC BTK Degrader-10 Degrader / 否
HY-144170 RET-IN-14 Inhibitor / 否
HY-143730 BTK inhibitor 20 Inhibitor / 否
HY-156745 DDa-1 Degrader / 否
HY-143717 JAK3/BTK-IN-2 Inhibitor / 否
HY-143718 JAK3/BTK-IN-3 Inhibitor / 否
HY-141689 BTK-IN-3 Inhibitor / 否
HY-170324 BTK-IN-40 Inhibitor / 否
HY-164002 PF-303 Inhibitor / 否
HY-145884 BTK-IN-8 Inhibitor / 否
HY-122828 PROTAC BTK Degrader-2 Degrader / 否
HY-153705 BTK-IN-25 Inhibitor / 否
HY-155072 PROTAC BTK Degrader-5 Degrader / 否
HY-168427 Avitinib maleate dihydrate Inhibitor / 否
HY-159589 BTK-IN-37 Inhibitor / 否
HY-139881 BTK inhibitor 19 Inhibitor / 否
HY-161876 GSTO1-IN-2 Inhibitor / 否
HY-169307 BTK-IN-38 Inhibitor / 否
HY-147754 JAK3/BTK-IN-6 Inhibitor / 否
HY-128403 BTK inhibitor 8 Inhibitor / 否
HY-13036C (Rac)-IBT6A hydrochloride Inhibitor / 否
HY-18016 CGI 560 Inhibitor / 否
HY-160142 UBX-382 Degrader 96.20% 否
HY-160167 BTK-IN-30 Inhibitor / 否
HY-168292 BTK ligand 9 / 否
HY-160168 BTK-IN-31 Inhibitor / 否
HY-102036 G-744 Inhibitor / 否
HY-117900 PF-06250112 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Btk NCBI NCBI:695
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z